American Association Of Clinical Endocrinologists (AACE) Endorses Measurement Of Low-Density Lipoprotein Particle (LDL-P) Number

LipoScience, Inc. LPDX, a diagnostic company pioneering a new field of personalized NMR diagnostics to advance the quality of patient care in cardiovascular, metabolic and other diseases, today announced that the American Association of Clinical Endocrinologists (AACE) has endorsed the measurement of low-density lipoprotein particles (LDL-P) as part of a management strategy to reduce the risk of cardiovascular disease (CVD) in patients with diabetes. The recommendation to measure LDL-P by NMR appears in the AACE's Comprehensive Diabetes Management Algorithm 2013 Consensus Statement, published in a supplement to the May/June issue of Endocrine Practice. The consensus statement cites expert opinion that LDL-P "must be recognized and included in treatment recommendations," noting that patients with type 2 diabetes, insulin resistance, metabolic syndrome, and/or hypertriglyceridemia (elevated triglycerides) are the most likely populations to have persistently elevated LDL-P, even when low-density lipoprotein cholesterol (LDL-C) and non-high-density lipoprotein cholesterol (non-HDL-C) are at goal levels. In presenting a new algorithm for the comprehensive management of persons with type 2 diabetes, the AACE consensus statement incorporates a CVD Risk Factor Modifications Algorithm that specifies desirable levels of LDL-P in at-risk patients. For patients at moderate risk of CVD (age younger than 40 years and/or no major risk factors aside from diabetes), an LDL-P level of less than 1200 nanomoles per liter (nmol/L) is considered desirable. For patients at high risk of CVD (diabetes plus one or more major risk factor, such as hypertension, family history, low HDL-C, or smoking), the desirable LDL-P level is less than 1000 nmol/L, according to the algorithm. "The AACE consensus statement reflects the growing recognition of low-density lipoprotein particle measurement by NMR as an important risk management tool in patients with diabetes and other cardiovascular risk factors," stated Richard O. Brajer, chief executive officer of LipoScience. "The endorsement of such a respected organization supports our vision of widespread adoption of LDL-P testing for CVD management." About LipoScience LipoScience, Inc. is pioneering a new field of personalized diagnostics based on nuclear magnetic resonance (NMR) technology. The company's first proprietary diagnostic test, the NMR LipoProfile® test, measures the number of low-density lipoprotein particles (LDL-P) in a blood sample and provides physicians and their patients with actionable information to personalize management of risk for heart disease. To date, over 10 million NMR LipoProfile tests have been ordered. LipoScience's automated clinical analyzer, Vantera®, has been cleared by the U.S. Food and Drug Administration (FDA). It requires no previous knowledge of NMR technology to operate and has been designed to dramatically simplify complex technology through ease of use and walk-away automation. The Vantera Clinical Analyzer will be placed with national and regional clinical laboratories. LipoScience is driving NMR diagnostics toward becoming a clinical standard of care by decentralizing its technology and expanding its menu of personalized diagnostic tests to address a broad range of cardiovascular, metabolic and other diseases. For further information on LipoScience, please visit www.liposcience.com and www.theparticletest.com.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsFDA
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!